日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer

循环肿瘤DNA可预测转移性胃食管癌的预后

van Velzen, Merel J M; Creemers, Aafke; van den Ende, Tom; Schokker, Sandor; Krausz, Sarah; Reinten, Roy J; Dijk, Frederike; van Noesel, Carel J M; Halfwerk, Hans; Meijer, Sybren L; Mearadji, Banafsche; Derks, Sarah; Bijlsma, Maarten F; van Laarhoven, Hanneke W M

A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT).

一项针对一线治疗后晚期食管胃癌患者的瑞戈非尼和紫杉醇 Ib/II 期研究 (REPEAT)

Stroes Charlotte I, Schokker Sandor, Khurshed Mohammed, van der Woude Stephanie O, Mathôt Ron Aa, Slingerland Marije, de Vos-Geelen Judith, Zucchetti Massimo, Matteo Cristina, van Dijk Erik, Ylstra Bauke, Thijssen Victor, Derks Sarah, Godefa Tesfay, Dijksterhuis Willemieke, Breimer Gerben E, van Delden Otto M, Verhoeven Rob Ha, Meijer Sybren L, Bijlsma Maarten F, van Laarhoven Hanneke Wm

A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX

一项II期研究表明,对于可切除的食管腺癌,采用六个周期的S-1和奥沙利铂辅助治疗不可行,ERCC1可作为SOX疗效的生物标志物。

Stroes, Charlotte I; Schokker, Sandor; Molenaar, Remco J; Mathôt, Ron A A; Bijlsma, Maarten F; van der Woude, Stephanie O; Belo Pereira, João P; Hooijer, Gerrit K J; Verhoeven, Rob H A; Cats, Annemieke; Grootscholten, Cecile; van Sandick, Johanna W; Creemers, Geert-Jan; Nieuwenhuijzen, Grard A P; Haj Mohammad, Nadia; Ruurda, Jelle P; Meijer, Sybren L; Hulshof, Maarten C C M; van Berge Henegouwen, Mark I; van Laarhoven, Hanneke W M

Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study

曲妥珠单抗和帕妥珠单抗联合放化疗治疗可切除的人表皮生长因子受体2阳性食管腺癌的II期可行性和生物标志物研究:TRAP研究

Stroes, Charlotte I; Schokker, Sandor; Creemers, Aafke; Molenaar, Remco J; Hulshof, Maarten C C M; van der Woude, Stephanie O; Bennink, Roel J; Mathôt, Ron A A; Krishnadath, Kausilia K; Punt, Cornelis J A; Verhoeven, Rob H A; van Oijen, Martijn G H; Creemers, Geert-Jan; Nieuwenhuijzen, Grard A P; van der Sangen, Maurice J C; Beerepoot, Laurens V; Heisterkamp, Joos; Los, Maartje; Slingerland, Marije; Cats, Annemieke; Hospers, Geke A P; Bijlsma, Maarten F; van Berge Henegouwen, Mark I; Meijer, Sybren L; van Laarhoven, Hanneke W M

Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma

循环肿瘤DNA含量与肿瘤体积相关,两者均可预测转移性胰腺导管腺癌患者的生存期。

Strijker, Marin; Soer, Eline C; de Pastena, Matteo; Creemers, Aafke; Balduzzi, Alberto; Beagan, Jamie J; Busch, Olivier R; van Delden, Otto M; Halfwerk, Hans; van Hooft, Jeanin E; van Lienden, Krijn P; Marchegiani, Giovanni; Meijer, Sybren L; van Noesel, Carel J; Reinten, Roy J; Roos, Eva; Schokker, Sandor; Verheij, Joanne; van de Vijver, Marc J; Waasdorp, Cynthia; Wilmink, Johanna W; Ylstra, Bauke; Besselink, Marc G; Bijlsma, Maarten F; Dijk, Frederike; van Laarhoven, Hanneke W

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study).

在转移性食管胃腺癌的一线治疗中,将纳米白蛋白紫杉醇添加到卡培他滨和奥沙利铂(CapOx)中,进行 I 期剂量递增研究及扩展队列研究(ACTION 研究)

Schokker Sandor, van der Woude Stephanie O, van Kleef Jessy Joy, van Zoen Daan J, van Oijen Martijn G H, Mearadji Banafsche, Beenen Ludo F M, Stroes Charlotte I, Waasdorp Cynthia, Jibodh R Aarti, Creemers Aafke, Meijer Sybren L, Hooijer Gerrit K J, Punt Cornelis J A, Bijlsma Maarten F, van Laarhoven Hanneke W M